Schizophrenia News

A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.

Volunteer-based biobanks can provide insight into people with less severe forms of illnesses like schizophrenia compared with samples recruited from clinical settings, according to a study published in JAMA Psychiatry.

Adults with strabismus were more likely to have mental health conditions, including anxiety, depression and substance use and addiction, compared with those without strabismus, according to a study published in JAMA Ophthalmology.

According to results published in Orthopedics, patients with vs. without psychiatric diagnoses, such as depression, bipolar disorder, anxiety disorder and schizophrenia, had similar clinical outcomes after fracture-related infection.

A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

Three weeks of 1-Hz repetitive transcranial magnetic stimulation effectively alleviated psychomotor slowing among people with schizophrenia spectrum disorder, according to a study published in JAMA Psychiatry.

Epidemiological data show women with schizophrenia are 63% more likely to develop CVD during 3.5 years of follow-up compared with those without the condition, with a greater risk observed for women with obesity.

The FDA has declined to approve a new drug application for roluperidone to treat negative symptoms in individuals with schizophrenia.

Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.